Mostrando ítems 1-10 de 10

    • Advances in hepatitis B therapeutics 

      Soriano, Vicente ; Barreiro, Pablo; Cachay, Edward R.; Kottilil, Shyamasundaran; Fernandez-Montero, José V.; Mendoza, Carmen de (Therapeutic Advances in Infectious Disease, 10/2020)
      Despite the availability of both effective preventive vaccines and oral antivirals, over 250 million people are chronically infected with the hepatitis B virus (HBV). Globally, chronic hepatitis B is the leading cause of ...
    • Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy 

      Soriano, Vicente; Moreno-Torres, Víctor; Treviño, Ana; Corral, Octavio Jorge; de Mendoza, Carmen (Drug Design, Development and Therapy, 2023)
      It has been ten years since the identification of NTCP as the cell surface receptor for HBV and HDV entry into hepatocytes. The search for molecules interfering with the binding of NTCP and HBV/HDV led to design bulevirtide ...
    • Envisioning a hepatitis delta cure with new antivirals 

      Soriano, Vicente ; Mendoza, Carmen de; Barreiro, Pablo; Treviño, Ana ; Corral, Octavio Jorge (Future Medicine Ltd., 2021)
      Envisioning a hepatitis delta cure with new antivirals
    • Envisioning hepatitis delta cure without functional hepatitis B cure 

      Soriano, Vicente; de Mendoza, Carmen; Barreiro, Pablo (AIDS reviews, 2022)
      [abstract not available]
    • Hepatitis delta in patients hospitalized in Spain (1997-2018) 

      Ramos-Rincón, José-Manuel; Pinargote-Celorio, Héctor; Ramos-Belinchón, Clara; de Mendoza, Carmen; Aguilera, Antonio; Soriano, Vicente (NLM (Medline), 2021)
      BACKGROUND: Hepatitis delta is the most aggressive form of chronic viral hepatitis. We examined the clinical burden, epidemiological features and time trends for hepatitis delta patients hospitalized in Spain during the ...
    • Hepatitis delta in patients with resolved hepatitis B virus infection 

      Aguilera, Antonio; Rodríguez-Calviño, Javier; Mendoza, Carmen de; Soriano, Vicente (European Journal of Gastroenterology & Hepatology, 09/2018)
      Background The hepatitis delta virus (HDV) causes the most aggressive form of chronic viral hepatitis. As HDV replication requires hepatitis B virus (HBV), HDV screening is limited to HBsAg+ carriers. To date, individuals ...
    • Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain 

      Ramos-Rincón, José-Manuel; Pinargote-Celorio, Héctor; de Mendoza, Carmen; Ramos-Belinchón, Clara; Barreiro, Pablo; Treviño, Ana; Corral, Octavio Jorge; Soriano, Vicente (Hepatology International, 2022)
      Background: Chronic viral hepatitis B, C, and D are the main causes of decompensated cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented more than 2 decades ago in most EU countries. Furthermore, ...
    • Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain 

      Aguilera, Antonio; Trastoy, Rocío; Rodríguez-Calviño, Javier; Manso, Tamara; Mendoza, Carmen de; Soriano, Vicente (European Journal of Gastroenterology & Hepatology, 09/2018)
      Background Hepatitis delta virus (HDV) is a defective agent that only replicates in the presence of the hepatitis B virus. Accordingly, HDV acquisition may occur as superinfection of HBsAg+ carriers or following acute dual ...
    • Treatment of hepatitis delta and HIV infection 

      Soriano, Vicente; de Mendoza, Carmen; Treviño, Ana; Ramos-Rincón, José-Manuel; Moreno-Torres, Víctor; Corral, Octavio Jorge; Barreiro, Pablo (Liver International, 2023)
      Hepatitis delta virus (HDV) is a defective agent that only infects individuals with hepatitis B virus (HBV). Around 5–10% of chronic hepatitis B patients worldwide are superinfected with HDV, which means 15–25 million ...
    • Viral hepatitis in persons living with HIV in the post-COVID era 

      Soriano, Vicente; Moreno-Torres, Víctor; de Mendoza, Carmen; Corral, Octavio Jorge; Barreiro, Pablo (AIDS reviews, 2023)
      Coinfection with hepatitis viruses A to E is frequent in persons living with HIV (PLWH) and causes significant morbidity and mortality. Oro-fecal transmissible hepatitis A and E mostly produce acute self-limited episodes ...